MX9701776A - Uso de factores de crecimiento similares a insulina i y ii para la inhibicion de la respuesta inflamatoria. - Google Patents

Uso de factores de crecimiento similares a insulina i y ii para la inhibicion de la respuesta inflamatoria.

Info

Publication number
MX9701776A
MX9701776A MX9701776A MX9701776A MX9701776A MX 9701776 A MX9701776 A MX 9701776A MX 9701776 A MX9701776 A MX 9701776A MX 9701776 A MX9701776 A MX 9701776A MX 9701776 A MX9701776 A MX 9701776A
Authority
MX
Mexico
Prior art keywords
inflammatory response
insulin
inhibition
growth factors
igf
Prior art date
Application number
MX9701776A
Other languages
English (en)
Inventor
Philip Francis Halloran
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX9701776A publication Critical patent/MX9701776A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
    • F04B39/00—Component parts, details, or accessories, of pumps or pumping systems specially adapted for elastic fluids, not otherwise provided for in, or of interest apart from, groups F04B25/00 - F04B37/00
    • F04B39/0005—Component parts, details, or accessories, of pumps or pumping systems specially adapted for elastic fluids, not otherwise provided for in, or of interest apart from, groups F04B25/00 - F04B37/00 adaptations of pistons
    • F04B39/0016—Component parts, details, or accessories, of pumps or pumping systems specially adapted for elastic fluids, not otherwise provided for in, or of interest apart from, groups F04B25/00 - F04B37/00 adaptations of pistons with valve arranged in the piston
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
    • F04B39/00—Component parts, details, or accessories, of pumps or pumping systems specially adapted for elastic fluids, not otherwise provided for in, or of interest apart from, groups F04B25/00 - F04B37/00
    • F04B39/10—Adaptations or arrangements of distribution members
    • F04B39/1073—Adaptations or arrangements of distribution members the members being reed valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00—Fluid handling
    • Y10T137/7722—Line condition change responsive valves
    • Y10T137/7837—Direct response valves [i.e., check valve type]
    • Y10T137/7879—Resilient material valve
    • Y10T137/7888—With valve member flexing about securement
    • Y10T137/7891—Flap or reed
    • Y10T137/7892—With stop

Abstract

La presente invencion se refiere a métodos para utilizar factor de crecimiento similar a insulina como inhibidor de la respuesta inflamatoria, de lesion isquémica, y de rechazo de organo.
MX9701776A 1994-09-08 1995-08-29 Uso de factores de crecimiento similares a insulina i y ii para la inhibicion de la respuesta inflamatoria. MX9701776A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30249494A 1994-09-08 1994-09-08
PCT/EP1995/003393 WO1996007424A1 (en) 1994-09-08 1995-08-29 Use of insulin-like growth factors (i) and (ii) for inhibition of inflammatory response

Publications (1)

Publication Number Publication Date
MX9701776A true MX9701776A (es) 1997-10-31

Family

ID=23167961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701776A MX9701776A (es) 1994-09-08 1995-08-29 Uso de factores de crecimiento similares a insulina i y ii para la inhibicion de la respuesta inflamatoria.

Country Status (11)

Country Link
US (3) US5712249A (es)
EP (2) EP1764106A3 (es)
JP (1) JPH10505076A (es)
KR (1) KR100429752B1 (es)
AU (1) AU710303B2 (es)
CA (1) CA2198018A1 (es)
IL (1) IL115118A (es)
MX (1) MX9701776A (es)
NZ (1) NZ292540A (es)
WO (1) WO1996007424A1 (es)
ZA (1) ZA957512B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7193042B1 (en) * 1995-06-07 2007-03-20 Chiron Corporation Methods for purifying authentic IGF from yeast hosts
US7071313B1 (en) * 1995-06-07 2006-07-04 Cephalon, Inc. Methods of purifying authentic IGF from yeast hosts
DE19544233A1 (de) * 1995-11-28 1997-06-05 Hoechst Ag Verfahren zur Nutzung des Hefe-ADH II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten
FR2756845B1 (fr) * 1996-12-06 1999-02-26 Genset Sa Sequence nucleotidique codant pour une flavine monooxygenase , proteine correspondante et composition destinee au diagnostic et a la therapie du glaucome
US7074762B2 (en) 1998-01-05 2006-07-11 Washington University Composition and method for improving function of embryonic kidney transplants
WO1999051262A2 (en) * 1998-04-03 1999-10-14 Chiron Corporation Use of igfi for treating articular cartilage disorders
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
ES2308985T3 (es) * 1999-07-21 2008-12-16 Omeros Corporation Disoluciones y procedimientos para la inhibicion del dolor, inflamacion y degradacion del cartilago.
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
AU2006275444B2 (en) 2005-08-01 2010-10-28 Genera Istrazivanja D.O.O. Methods and compositions for regenerating articular cartilage
US20080020982A1 (en) * 2006-07-21 2008-01-24 Patrice Delafontaine Methods and compositions for treatment of atherosclerosis
CN102612373B (zh) * 2009-11-11 2016-03-02 国立大学法人山口大学 消化器官疾病治疗剂
EP2763692A2 (en) * 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
US9675671B2 (en) * 2014-01-12 2017-06-13 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341302C (en) * 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
EP0561137B1 (en) * 1983-04-25 2002-07-03 Chiron Corporation Hybrid DNA Synthesis of Mature Insulin-like Growth Factors
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
JPS6035476A (ja) * 1983-08-05 1985-02-23 日新電機株式会社 接続断路用接栓
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US5028531A (en) * 1984-03-19 1991-07-02 Fujisawa Pharmaceutical Company, Ltd. IGF-I fusion proteins; protection of IGF-I from degradation by host cell; and processes for the production thereof
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
DE3783305T2 (de) * 1986-10-09 1993-05-19 Fujisawa Pharmaceutical Co Expressionsvektor fuer menschlichen insulinaehnlichen wachstumsfaktor-i.
JPH01500199A (ja) * 1986-11-14 1989-01-26 インスティチュート・オブ・モレキュラー・バイオロジー・インコーポレーテッド 創傷の治癒および骨の再生
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0289477A3 (en) * 1987-04-28 1989-03-08 Valmet Paper Machinery Inc. Method for hot-pressing of a paper web and a drying device for the implementation of the method
JPS6458013A (en) * 1987-08-20 1989-03-06 Ibm Method and data processing system for guaranteeing large area identification and management of data memory
GB8723660D0 (en) * 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
FR2649120B1 (fr) * 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
WO1991001720A1 (en) * 1989-08-07 1991-02-21 Herman Wade Schlameus Composition and method of promoting hard tissue healing
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
DE69019727T2 (de) * 1989-09-21 1995-10-19 Idemitsu Kosan Co Arylstyrolpolymer und -copolymer und verfahren zu ihrer herstellung.
ZA9010332B (en) * 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
WO1992004363A1 (en) * 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
IL99526A0 (en) * 1990-09-28 1992-08-18 Lilly Co Eli Expression vector construction utilizing viral sequences for selective expression of useful substances
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
SE9101840L (sv) * 1991-06-14 1992-12-15 Kabi Pharmacia Ny medicinsk anvaendning
EP0597033B1 (en) * 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
AU673659B2 (en) * 1991-11-25 1996-11-21 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
TW267102B (es) * 1992-03-13 1996-01-01 Ciba Geigy
JPH07505161A (ja) * 1992-03-18 1995-06-08 オステオサ　インコーポレイテッド 新規な枝角−由来の骨成長因子
JPH06510065A (ja) * 1992-06-08 1994-11-10 カイロン　コーポレーション 成長因子ｉｇｆ−ｉおよび／またはｉｇｆ−ｉｉの用法
NZ243071A (en) * 1992-06-08 1994-09-27 Kabi Pharmacia Ab Igf-2 (or analogue) compositions for pharmaceutical uses
DK0659083T3 (da) * 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
ATE226958T1 (de) * 1993-09-20 2002-11-15 Celtrix Pharma Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法

Also Published As

Publication number Publication date
NZ292540A (en) 1999-08-30
EP0779816A1 (en) 1997-06-25
AU3474095A (en) 1996-03-27
US5843899A (en) 1998-12-01
KR970705407A (ko) 1997-10-09
KR100429752B1 (ko) 2004-07-16
JPH10505076A (ja) 1998-05-19
US5712249A (en) 1998-01-27
ZA957512B (en) 1996-05-23
IL115118A0 (en) 1995-12-08
EP1764106A2 (en) 2007-03-21
EP1764106A3 (en) 2007-04-04
US5728676A (en) 1998-03-17
WO1996007424A1 (en) 1996-03-14
AU710303B2 (en) 1999-09-16
CA2198018A1 (en) 1996-03-14
IL115118A (en) 2006-08-20

Similar Documents

Publication Publication Date Title
MX9701776A (es) Uso de factores de crecimiento similares a insulina i y ii para la inhibicion de la respuesta inflamatoria.
AP9901478A0 (en) Compounds for the treatment of ischemia.
MY102705A (en) Proline derivaties and related compounds.
PL327735A1 (en) Novel substituted derivatives of imidazole
PL327934A1 (en) Novel substituted imidazole compounds
NO942064L (no) yminhibitorer
EP0283675A3 (en) Dental plaque and dental caries inhibiting agent and compositions containing such an agent
EP0766676A4 (en) COMPOUNDS AND METHOD FOR INHIBITING PHOSPHODIESTERASE IV
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
DE69725153D1 (de) Kaliumkanal-blocker
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
AU2938477A (en) Dicaroboxylic ester-acids for use as rust or corrosian inhibitors
BG99177A (en) New 7 -substituted-4-aza-5 - cholestanones as inhibitors of 5 - reductase
BG104719A (en) Glucocorticoid-selective anti-inflammatory agents
PL333429A1 (en) Benzonaphtyridines useful in particular in treating bronchial diseases
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
EP0310072A3 (en) Non-peptidyl beta-succinamidoacyl aminodiols as anti-hypertensive agents
IL126235A0 (en) Compounds with growth hormone releasing properties
MX9801190A (es) Inhibidores de prolil endopeptidasa.
DE69228814T2 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
GB2324091A (en) Metalloproteinase inhibitors
ES8205126A1 (es) Un procedimiento para la preparacion de un inhibidor del enzima convertidor de la angiotensina.
DK0506716T3 (da) Fremgangsmåde til behandling af trombocytopeni og farmaceutiske præparater egnet dertil
MX9701764A (es) Derivados de imidoacidos.